hold rate reect skeptic
compani attain sale growth margin target recent meet
manag challeng view
still comfort estim plan
street nonetheless longer see valuat discount warrant
rais price target accordingli
portfolio strateg coher optim latter inning plenti
organ inorgan runway
messag around portfolio mix shift versu year ago
compani character sale focu area reproduct
health emerg market diagnost food biopharma servic
sale origin focu market food pharma diagnost
market demograph tailwind new product cycl sale industri
academ market lesser prioriti see
sale potenti prune block
compani plenti organ inorgan runway focu market
autoimmun diagnost euroimmun annual organ month
perkinelm genom whole genom sequenc newborn
inorgan compani would interest bolster consum
portfolio discoveri analyt solut da busi unit
consolid fragment food analysi market broader capabl
qualiti control test deeper expans food safeti test interest
acquisit privat compani sound feasibl public target
year end expect return target leverag ratio
net debt/ebitda could back market meaning
transact compani will expand leverag net debt/
ebitda right transact pathway toward return leverag
month framework suggest could start next year
dri powder
growth acceler algorithm overli depend one item seem
feasibl follow strong
price sep usd
valuat price target reect
enterpris valu use project level
debt cash ebitda ex
option estim end
multipl line
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar rm may conict interest could aect object report investor consid
report singl factor make invest decis disclosur analyst certif
path high-singl digit organ sale growth still strike us
stretch certainli appear feasibl follow strong rais
guid organ sale growth includ euroimmun best
infer path look someth like core growth trend-line averag
organ sale growth improv end market
euroimmun vanadi nipt perkinelm genom target
gentl eort drive cost synergi euroimmun
jeopard growth rate see meaning opportun expand
presenc euroimmun sale gener
compani consid vanadi nipt test transform see
meaning growth contribut modest penetr assumpt
within current european biochem test busi test annual
skeptic vanadi opportun see data thought
summar might come late earli
like view clinic trial data could avail late trial
detail believ sale estim vanadi diverg
think least promin piec varianc
organ sale growth assumpt expect
diverg model compani think
sale forecast perkinelm genom busi oer clinic
whole genom whole exom sequenc newborn well pharma
servic forecast compar compani target increasingli
think estim overli conserv follow demand year-to-d compani
meaning expand capac meet demand recent call
nextgen sequenc expert commun pharma interest
servic sale pharma could compris target
margin ramp driver also manifold waypoint nal destin
path ebit margin also strike
us stretch compani see driver achiev goal roughli
equal weight driver product mix faster growth
higher margin diagnost busi vs da volum leverag compris
increas util exist da manufactur footprint current
util sg leverag grow half rate sale
growth procur compil eort optim compani
direct indirect spend moreov consid margin target
waypoint path continu margin expans rather termin goal
model ebit margin consist street
perhap overli conserv think histori side
compani miss two previou mid-term margin object narrowli
miss target result boost lower
plan spend fell percent sale vs
hire ramp new hopkinton campu lag expect compani also
miss target
forecast ratio
period end expens expens incom incom continu ep dilut con share share sale ex amort acquir cash flowoper cash cash revenu ep incl compani non-gaap present exclud acquir intang amortizaton
period end asset equival st receiv current discontinu current equip secur asset asset asset discontinu liabil short-term liabil discontinu op current debt less current long-term liabil stockhold split ap accrual septemb
